DALLAS--(BUSINESS WIRE)--HemoBioTech (OTCBB: HMBT, www.hemobiotech.com), a developmental biopharmaceutical company focused on developing and commercializing potentially the first viable human blood substitute, was featured nationally on Fox News. HemoBioTech was featured on Fox affiliate stations in 13 markets, including New York, Dallas-Ft. Worth, Phoenix, Indianapolis, Nashville, Milwaukee and Austin, TX. The broadcast network currently leads the cable news market in the United States averaging 3.3 million viewers daily.
